Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?
Authors
Keywords
-
Journal
TOXICOLOGICAL SCIENCES
Volume 149, Issue 1, Pages 237-250
Publisher
Oxford University Press (OUP)
Online
2016-01-05
DOI
10.1093/toxsci/kfv231
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function
- (2015) Wendy E. Boertien et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Mechanisms of tolvaptan-induced toxicity in HepG2 cells
- (2015) Yuanfeng Wu et al. BIOCHEMICAL PHARMACOLOGY
- Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
- (2015) Paul B. Watkins et al. DRUG SAFETY
- Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid–Mediated Troglitazone Hepatotoxicity
- (2014) K Yang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges
- (2014) John R. Senior DRUG SAFETY
- Tolvaptan for the treatment of liver cirrhosis oedema
- (2014) Isao Sakaida Expert Review of Gastroenterology & Hepatology
- Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury
- (2014) Jeffrey L. Woodhead et al. Frontiers in Pharmacology
- Review of Tolvaptan’s Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions
- (2014) Purav Bhatt et al. Journal of Clinical Medicine
- Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function
- (2013) Susan E. Shoaf et al. KIDNEY INTERNATIONAL
- A Multifactorial Approach to Hepatobiliary Transporter Assessment Enables Improved Therapeutic Compound Development
- (2013) Ryan E. Morgan et al. TOXICOLOGICAL SCIENCES
- A membrane vesicle-based assay to enable prediction of human biliary excretion
- (2013) Federico Colombo et al. XENOBIOTICA
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
- (2012) Vicente E. Torres et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endogenous bile acid disposition in rat and human sandwich-cultured hepatocytes
- (2012) Tracy L. Marion et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects
- (2011) Susan E. Shoaf et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and Safety of Tolvaptan in Heart Failure Patients with Sustained Volume Overload despite the Use of Conventional Diuretics: A Phase III Open-Label Study
- (2011) Masatake Fukunami et al. CARDIOVASCULAR DRUGS AND THERAPY
- Pharmacokinetics, Pharmacodynamics and Safety of Tolvaptan, A Novel, Oral, Selective Nonpeptide AVP V2-receptor Antagonist: Results of Single- and Multiple-Dose Studies in Healthy Japanese Male Volunteers
- (2011) Seong Ryul Kim et al. CARDIOVASCULAR DRUGS AND THERAPY
- Nonclinical Safety Profile of Tolvaptan
- (2011) Akihide Oi et al. CARDIOVASCULAR DRUGS AND THERAPY
- Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience
- (2011) E. Higashihara et al. Clinical Journal of the American Society of Nephrology
- Drug-induced cholestasis
- (2011) Manmeet S. Padda et al. HEPATOLOGY
- Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signali
- (2011) Jin Chai et al. HEPATOLOGY
- Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects
- (2011) Susan E. Shoaf et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Sandwich-cultured hepatocytes: anin vitromodel to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity
- (2010) Brandon Swift* et al. DRUG METABOLISM REVIEWS
- Interference with Bile Salt Export Pump Function Is a Susceptibility Factor for Human Liver Injury in Drug Development
- (2010) Ryan E. Morgan et al. TOXICOLOGICAL SCIENCES
- New molecular insights into the mechanisms of cholestasis
- (2009) Martin Wagner et al. JOURNAL OF HEPATOLOGY
- Role of Hepatic Transporters in the Disposition and Hepatotoxicity of a HER2 Tyrosine Kinase Inhibitor CP-724,714
- (2009) Bo Feng et al. TOXICOLOGICAL SCIENCES
- Bile-acid-induced cell injury and protection
- (2009) Maria J Perez et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Bile Acids: Chemistry, Pathochemistry, Biology, Pathobiology, and Therapeutics
- (2008) A. F. Hofmann et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process
- (2008) Shiew-Mei Huang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Absence of glycochenodeoxycholic acid (GCDCA) in human bile is an indication of cholestasis: A1H MRS study
- (2008) Omkar B. Ijare et al. NMR IN BIOMEDICINE
- Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis
- (2007) S Teng et al. BRITISH JOURNAL OF PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started